

Special Issue

Drug Candidates for Inflammatory Diseases

Message from the Guest Editor

Inflammation represents the hallmark of diverse acute and chronic diseases. Multiple molecular pathways are known, and a multitude of therapeutic substance classes are described. However, the complex immune response and its dysregulation in inflammation still presents a challenge for the pharmacological treatment of such conditions. Therefore, there is an unmet need for new drug candidates for inflammatory diseases. Potential new approaches include small molecules, phytochemicals, liposomal formulations or nanomedicine. This Special Issue of *Molecules* invites contributions from all scientific fields that are connected to drug research for inflammatory diseases and will provide a forum for the exchange of new concepts and original results from in vitro to in vivo studies.

Guest Editor

Prof. Dr. Christian Lehmann

Department of Anesthesiology, Dalhousie University, Halifax, NS, Canada

Deadline for manuscript submissions

closed (31 December 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/172108

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).